ABC6 - March 5, 2007
Temple's Center for Obesity Research and Education (CORE) is seeking volunteers for a clinical trial to test a new weight drug. The drug combines small doses of 2 medications – bupropion, better known as Welbutrin, which is used to stop smoking, and naltrexone, which is used for alcohol addiction. Gary Foster, PhD, director of CORE, said he hopes study participants will be able to lose 8 to 10 percent of their body weight. It should yield big health rewards. "A small amount of weight loss, like 5 to 10 percent, can have powerful effects on blood pressure, blood glucose, and cholesterol. Even a 5 percent weight loss can reduce the chance of developing type 2 diabetes by 60 percent."